Many tumors demonstrated heterogeneous and relatively low uptake in CCK2R-positive tumors (average lesion SUVmax 6.8).13 Only two of eighteen patients with exceptionally high tumor uptake (SUVmax > 34) were considered suitable for [177Lu]Lu-DOTA-CP04 therapy, clearly indicating the need for improved agents that optimize tumor targeting while retaining minimal physiological uptake.17,18. Here, CCKBR is linked to neoplasm.